Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
about
Pramipexole-induced somnolence and episodes of daytime sleep.Ropinirole and pramipexole, the new agonists.New drugs for the treatment of Parkinson's disease.Pre-clinical studies of pramipexole: clinical relevance.A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonistA review of pramipexole and its clinical utility in Parkinson's disease.Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre studyDopamine receptors and Parkinson's diseaseAnimal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Pramipexole in the treatment of Parkinson's disease: new developments.Update on the use of pramipexole in the treatment of Parkinson's disease.Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence.Current status of symptomatic medical therapy in Parkinson's diseaseGDNF therapy for Parkinson's disease.Effects of pramipexole treatment on the α-synuclein content in serum exosomes of Parkinson's disease patientsDopamine receptor agonists for Parkinson's disease.Pramipexole extended-release: a review of its use in patients with Parkinson's disease.Pramipexole reduces inflammation in the experimental animal models of inflammation.Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats.Rotation and immediate-early gene expression in rats treated with the atypical D1 dopamine agonist SKF 83822.Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks".Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients.N-oleoyl-dopamine increases locomotor activity in the rat.A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease.Steady-state pharmacokinetic properties of pramipexole in healthy volunteers.Animal Toxins as Therapeutic Tools to Treat Neurodegenerative Diseases.
P2860
Q31422765-19B6F5EC-5520-4418-AE9C-90C071247403Q33714127-3E80B711-3A73-424B-A0C6-02C1FA3870C8Q33821342-AFCF6674-6AA0-4ECC-8FA7-F6EBDD4B88C2Q34071719-ED59F0A6-B200-45C3-8DEC-7AE979D456D7Q34431032-23756726-FA75-4483-9D10-F0EC3063F817Q34519277-287D8152-D2D8-463E-9179-6659460B1026Q35468072-DFDF187C-045D-4589-AC0A-4A4F2BC91984Q35545020-B8DFA344-9058-4CD7-979E-5E565ECC8B45Q35589979-18CD667D-D7F7-49BF-8453-0B22EEF45024Q36257184-75FF894E-2DC1-41FA-A8D0-70C43102B122Q36842189-CCA751D9-4759-48DB-89F9-53546AD16184Q36878368-8E45947C-7CD5-4C61-9ABF-E98D6529B30EQ37131229-076014AA-F747-4DF7-8B0D-71ECF4404740Q37203371-13BF5F45-4469-453D-920C-733ED862718BQ37204488-C3E04E51-4BE8-44C2-955A-1F16F87C514AQ38169202-AC73BB36-F76F-4210-9FB3-0E3076E8F0EEQ38266818-596BEE08-50BC-4941-B91B-94BCAC7658B0Q38978473-86E9E6F0-7A74-4331-8B67-F0AD2E998EBEQ40440490-1E7B6FCD-FC86-45B5-ACC8-18F696DB482BQ42616337-13779533-2F94-4BC0-8DF2-35B85A928135Q45076714-456AA340-4ED2-4BEA-8554-DE530299E871Q46566287-0E216431-27E5-449B-A25D-7AA75C23FF53Q47704925-B0D112B6-FB9B-4DD4-9A6C-30ACDEB9F342Q48339448-004DDACA-4AC4-46A9-9A07-B1BABC5C5CAEQ48766244-148B0360-37B2-4106-9B4A-45E8EBEC330BQ50948704-7AA2044E-BBDA-456A-8468-EDFB93F4AD01Q51764192-A0367E88-57FF-437A-B98A-DFCC3474581F
P2860
Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Biochemical and pharmacologica ...... dopamine D2 receptor agonist.
@en
Biochemical and pharmacologica ...... dopamine D2 receptor agonist.
@nl
type
label
Biochemical and pharmacologica ...... dopamine D2 receptor agonist.
@en
Biochemical and pharmacologica ...... dopamine D2 receptor agonist.
@nl
prefLabel
Biochemical and pharmacologica ...... dopamine D2 receptor agonist.
@en
Biochemical and pharmacologica ...... dopamine D2 receptor agonist.
@nl
P1476
Biochemical and pharmacologica ...... dopamine D2 receptor agonist.
@en
P2093
Schingnitz G
P304
P356
10.1016/0014-2999(92)90024-X
P407
P577
1992-05-01T00:00:00Z